Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MTL CEBPA

Drug Profile

MTL CEBPA

Alternative Names: MTL-CEBPA

Latest Information Update: 28 Oct 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MiNA Therapeutics; University of California at San Francisco; University of Texas Southwestern Medical Center
  • Developer MiNA Therapeutics; National University Hospital (Singapore)
  • Class Antineoplastics; Oligonucleotides; RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Liver cancer
  • Phase I/II Mucopolysaccharidosis I
  • Preclinical Acute myeloid leukaemia
  • No development reported Colorectal cancer; Liver disorders; Solid tumours

Most Recent Events

  • 28 Oct 2023 No recent reports of development identified for preclinical development in Colorectal-cancer in United Kingdom (IV)
  • 25 Oct 2023 MTL CEBPA is available for licensing as of 25 Oct 2023. 9401862
  • 25 Oct 2023 Preclinical trials in Acute myeloid leukaemia in United Kingdom prior to October 2023 (Parenteral)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top